Earnings: Medium

CWP

CWP: Property Developer - Riding the Housing Shortage Wave Before the Tide Turns

Updated 8 Oct 2025

Hold rating with $7.84 fair value vs $7.37 current price. Strong execution capabilities offset by inevitable margin compression as housing shortage normalises.

View note

cqe

CQE: Social Infrastructure REIT - Defensive Assets, Dangerous Concentration

Updated 8 Oct 2025

Market-leading social infrastructure REIT with 15.2% share faces critical tenant concentration and refinancing risks. Fair value $1.80 vs current $0.97, though probability-weighted analysis suggests $0.57 reflecting structural challenges.

View note

cos

COS: Asset Management Transformer - Service Evolution or Execution Illusion?

Updated 8 Oct 2025

COSOL trades at $0.60 vs $0.96 fair value amid AMaaS transformation. 13.4% revenue growth forecast, 14.8% peak margins by FY28. Quality score 5.7/10, narrow moat, high execution risk.

View note

cmm

CMM: Gold Mining Giant - Peak Prices, Peak Problems

Updated 8 Oct 2025

SELL rating with $5.20 fair value vs $12.51 current price. Industry-leading AISC of $1,468/oz but trading at 18.6x EV/EBITDA versus peer median 8.5x.

View note

cda

CDA: Defence Tech Darling - Peak Performance, Peak Peril

Updated 8 Oct 2025

STRONG SELL rating with 58% downside to $10.22 fair value. Peak 24.5% EBITDA margins face inevitable compression as technology commoditises.

View note

ccp

CCP: Debt Buying Dynamo - Transformation's Terminal Value Trap

Updated 8 Oct 2025

HOLD rating with $10.31 fair value vs $15.62 current price. Strong market leadership offset by 36% overvaluation and execution risk across multiple strategic initiatives.

View note

bsl

BSL: Steel Cycle Survivor - Trough to Peak Recovery Play

Updated 8 Oct 2025

BlueScope Steel analysis: Fair value $28.30 vs current $24.24 (16.7% upside). EBITDA margins recovering from 8.9% trough to 11.7% target. Multi-domestic strategy, net cash balance sheet.

View note

brg

BRG: Premium Appliance Powerhouse - When Perfect Execution Still Isn't Enough

Updated 8 Oct 2025

Trading at 30.0x EV/EBITDA (88% premium to peers), fair value $14.50 vs current $36.18 implies 60% downside despite strong operational metrics.

View note

bio

BIO: Probiotics Pioneer - Priced for Perfection, Positioned for Pain

Updated 8 Oct 2025

AVOID rating with fair value $0.229 vs current $0.52. First profitable year achieved but trading at 56.6x EV/EBITDA versus peer median 12.5x.

View note

bga

BGA: Dairy Giant - Spread Too Thin, Margins Melting

Updated 8 Oct 2025

Trading at $5.25 vs $4.65 fair value. EBITDA margins compressing 5.7% to 4.2%. Manufacturing consolidation targeting $30m savings amid private label pressure.

View note

ben

BEN: Regional Banking Transformation - Digital Dreams Meet Margin Reality

Updated 8 Oct 2025

Trading at $12.84 vs fair value $11.23, BEN faces margin compression and transformation execution risks despite Up platform momentum and community banking moat.

View note

bbn

BBN: Baby Retail Leader - Store of the Future or Store of the Past?

Updated 8 Oct 2025

Baby Bunting trades at $2.60 vs fair value $1.56, with 12.1% revenue growth forecast but 5.2/10 business quality score below peers.

View note